ZA201804534B - AQUEOUS PHARMACEUTICAL FORMULATION COMPRISING ANTI-PD-l-L1 ANTIBODY AVELUMAB - Google Patents
AQUEOUS PHARMACEUTICAL FORMULATION COMPRISING ANTI-PD-l-L1 ANTIBODY AVELUMABInfo
- Publication number
- ZA201804534B ZA201804534B ZA201804534A ZA201804534A ZA201804534B ZA 201804534 B ZA201804534 B ZA 201804534B ZA 201804534 A ZA201804534 A ZA 201804534A ZA 201804534 A ZA201804534 A ZA 201804534A ZA 201804534 B ZA201804534 B ZA 201804534B
- Authority
- ZA
- South Africa
- Prior art keywords
- pharmaceutical formulation
- aqueous pharmaceutical
- antibody avelumab
- avelumab
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15198233 | 2015-12-07 | ||
PCT/EP2016/002040 WO2017097407A1 (en) | 2015-12-07 | 2016-12-05 | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA201804534B true ZA201804534B (en) | 2020-11-25 |
Family
ID=54838201
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA201804534A ZA201804534B (en) | 2015-12-07 | 2018-07-06 | AQUEOUS PHARMACEUTICAL FORMULATION COMPRISING ANTI-PD-l-L1 ANTIBODY AVELUMAB |
Country Status (35)
Country | Link |
---|---|
US (2) | US11058769B2 (en) |
EP (2) | EP3747466A1 (en) |
JP (1) | JP6925337B2 (en) |
KR (1) | KR20180085801A (en) |
CN (1) | CN108367072B (en) |
AR (1) | AR107014A1 (en) |
AU (1) | AU2016368099C1 (en) |
BR (1) | BR112018010211A2 (en) |
CA (1) | CA3007481C (en) |
CL (1) | CL2018001488A1 (en) |
CO (1) | CO2018005525A2 (en) |
CY (1) | CY1123358T1 (en) |
DK (1) | DK3386541T3 (en) |
EA (1) | EA201891339A1 (en) |
ES (1) | ES2823279T3 (en) |
HK (1) | HK1257781A1 (en) |
HR (1) | HRP20201573T1 (en) |
HU (1) | HUE050811T2 (en) |
IL (1) | IL259563B (en) |
LT (1) | LT3386541T (en) |
MX (1) | MX2018006875A (en) |
MY (1) | MY195681A (en) |
NZ (1) | NZ743964A (en) |
PE (1) | PE20181400A1 (en) |
PH (1) | PH12018500894A1 (en) |
PL (1) | PL3386541T3 (en) |
PT (1) | PT3386541T (en) |
RS (1) | RS61029B1 (en) |
SA (1) | SA518391743B1 (en) |
SG (1) | SG11201804758QA (en) |
SI (1) | SI3386541T1 (en) |
TW (1) | TWI630917B (en) |
UA (1) | UA123270C2 (en) |
WO (1) | WO2017097407A1 (en) |
ZA (1) | ZA201804534B (en) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112014012819B1 (en) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | ANTI-PD-L1 ANTIBODY OR ANTIGEN BINDING FRAGMENT AND COMPOSITION |
WO2015048312A1 (en) | 2013-09-26 | 2015-04-02 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
JOP20200094A1 (en) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | Antibody molecules to pd-1 and uses thereof |
JOP20200096A1 (en) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | Antibody molecules to tim-3 and uses thereof |
WO2016040892A1 (en) | 2014-09-13 | 2016-03-17 | Novartis Ag | Combination therapies |
CN114920840A (en) | 2014-10-14 | 2022-08-19 | 诺华股份有限公司 | Antibody molecules against PD-L1 and uses thereof |
MX2017011644A (en) | 2015-03-13 | 2017-12-04 | Cytomx Therapeutics Inc | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof. |
CA3007481C (en) | 2015-12-07 | 2024-01-30 | Merck Patent Gmbh | Aqueous pharmaceutical formulation comprising anti-pd-l1 antibody avelumab |
UA126905C2 (en) | 2016-06-13 | 2023-02-22 | Ай-Маб Байофарма Юес Лімітед | Anti-pd-l1 antibodies and uses thereof |
IL265762B2 (en) | 2016-10-06 | 2024-04-01 | Merck Patent Gmbh | Dosing regimen of avelumab for the treatment of cancer |
CA3055402A1 (en) * | 2017-03-06 | 2018-09-13 | Merck Patent Gmbh | Aqueous anti-pd-l1 antibody formulation |
US11168144B2 (en) | 2017-06-01 | 2021-11-09 | Cytomx Therapeutics, Inc. | Activatable anti-PDL1 antibodies, and methods of use thereof |
WO2019085982A1 (en) * | 2017-11-02 | 2019-05-09 | 正大天晴药业集团南京顺欣制药有限公司 | Pharmaceutical composition containing anti-pd-l1 humanized monoclonal antibody |
US11034771B2 (en) | 2018-07-25 | 2021-06-15 | I-Mab Biopharma Us Limited | Anti-CD73 anti-PD-L1 bispecific antibodies |
WO2020060183A1 (en) * | 2018-09-18 | 2020-03-26 | 삼성바이오에피스 주식회사 | Liquid formation for stabilizing trastuzumab antibody |
CA3121288A1 (en) * | 2018-11-29 | 2020-06-04 | Harbour Biomed Therapeutics Limited | Anti-pd-l1 antibody preparation |
EP3927729A4 (en) | 2019-02-18 | 2023-10-11 | Eli Lilly and Company | Therapeutic antibody formulation |
TWI761869B (en) * | 2019-06-25 | 2022-04-21 | 大陸商信達生物製藥(蘇州)有限公司 | Formulation containing anti-cd47 / pd-l1 bispecific antibody and preparation and use thereof |
TW202114637A (en) * | 2019-08-22 | 2021-04-16 | 俄羅斯聯邦商拜奧卡德聯合股份公司 | Aqueous pharmaceutical composition of anti-pd1 antibody prolgolimab and use thereof |
WO2021118321A1 (en) * | 2019-12-13 | 2021-06-17 | 삼성바이오에피스 주식회사 | Stable anti-pd-1 antibody pharmaceutical preparation |
IL309662A (en) | 2021-07-02 | 2024-02-01 | Univ Yale | Compositions and methods for treating cancers |
WO2023034864A1 (en) | 2021-08-31 | 2023-03-09 | Yale University | Compositions and methods for treating cancers |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO3000B1 (en) * | 2004-10-20 | 2016-09-05 | Genentech Inc | Antibody Formulations. |
PT1934236E (en) | 2005-09-02 | 2012-12-26 | Glycomimetics Inc | Heterobifunctional pan-selectin inhibitors |
KR101378194B1 (en) | 2005-12-20 | 2014-03-27 | 브리스톨-마이어스 스큅 컴퍼니 | Stable protein formulations |
US8895510B2 (en) | 2008-04-08 | 2014-11-25 | Glycomimetics, Inc. | Pan-selectin inhibitor with enhanced pharmacokinetic activity |
TWI686405B (en) * | 2008-12-09 | 2020-03-01 | 建南德克公司 | Anti-pd-l1 antibodies and their use to enhance t-cell function |
EP2196476A1 (en) | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
MX2012007676A (en) * | 2009-12-29 | 2012-08-03 | Hoffmann La Roche | Antibody formulation. |
US8921328B2 (en) | 2010-09-14 | 2014-12-30 | Glycomimetics, Inc. | E-selectin antagonists |
KR102031020B1 (en) * | 2011-03-31 | 2019-10-14 | 머크 샤프 앤드 돔 코포레이션 | Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments |
BR112014012819B1 (en) * | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | ANTI-PD-L1 ANTIBODY OR ANTIGEN BINDING FRAGMENT AND COMPOSITION |
EA033387B1 (en) * | 2012-01-23 | 2019-10-31 | Regeneron Pharma | STABILIZED FORMULATIONS CONTAINING ANTI-Ang2 ANTIBODIES |
US9216219B2 (en) * | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
MA38960A1 (en) | 2013-09-27 | 2017-10-31 | Genentech Inc | Anti-pdl1 antibody formulations |
US10376582B2 (en) * | 2013-10-16 | 2019-08-13 | Outlook Therapeutics, Inc. | Buffer formulations for enhanced antibody stability |
US20170158776A1 (en) * | 2014-05-15 | 2017-06-08 | Bristol-Myers Squibb Company | Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent |
CN105085680A (en) * | 2014-05-23 | 2015-11-25 | 复旦大学 | Humanized anti-PD-1 and c-MET bispecific antibody, and preparation method and application thereof |
US10800846B2 (en) | 2015-02-26 | 2020-10-13 | Merck Patent Gmbh | PD-1/PD-L1 inhibitors for the treatment of cancer |
TW201705955A (en) | 2015-05-14 | 2017-02-16 | 輝瑞大藥廠 | Combination therapies comprising a pyrrolidine-2,5-dione IDO1 inhibitor and an anti-PD1/anti-PD-L1 antibody |
EP3303397A1 (en) | 2015-06-08 | 2018-04-11 | H. Hoffnabb-La Roche Ag | Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists |
WO2016205277A1 (en) | 2015-06-16 | 2016-12-22 | Merck Patent Gmbh | Pd-l1 antagonist combination treatments |
JP2018529719A (en) | 2015-09-30 | 2018-10-11 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | Combination of PD-1 system binding antagonist and ALK inhibitor for treating ALK negative cancer |
CA3007481C (en) | 2015-12-07 | 2024-01-30 | Merck Patent Gmbh | Aqueous pharmaceutical formulation comprising anti-pd-l1 antibody avelumab |
CA3055402A1 (en) | 2017-03-06 | 2018-09-13 | Merck Patent Gmbh | Aqueous anti-pd-l1 antibody formulation |
-
2016
- 2016-12-05 CA CA3007481A patent/CA3007481C/en active Active
- 2016-12-05 AU AU2016368099A patent/AU2016368099C1/en active Active
- 2016-12-05 UA UAA201807363A patent/UA123270C2/en unknown
- 2016-12-05 US US16/060,319 patent/US11058769B2/en active Active
- 2016-12-05 ES ES16818985T patent/ES2823279T3/en active Active
- 2016-12-05 PT PT168189850T patent/PT3386541T/en unknown
- 2016-12-05 SI SI201630940T patent/SI3386541T1/en unknown
- 2016-12-05 EP EP20184113.7A patent/EP3747466A1/en not_active Withdrawn
- 2016-12-05 SG SG11201804758QA patent/SG11201804758QA/en unknown
- 2016-12-05 EP EP16818985.0A patent/EP3386541B1/en active Active
- 2016-12-05 PE PE2018001077A patent/PE20181400A1/en unknown
- 2016-12-05 BR BR112018010211A patent/BR112018010211A2/en active Search and Examination
- 2016-12-05 HU HUE16818985A patent/HUE050811T2/en unknown
- 2016-12-05 MY MYPI2018702171A patent/MY195681A/en unknown
- 2016-12-05 WO PCT/EP2016/002040 patent/WO2017097407A1/en active Application Filing
- 2016-12-05 JP JP2018529213A patent/JP6925337B2/en active Active
- 2016-12-05 LT LTEP16818985.0T patent/LT3386541T/en unknown
- 2016-12-05 NZ NZ743964A patent/NZ743964A/en unknown
- 2016-12-05 DK DK16818985.0T patent/DK3386541T3/en active
- 2016-12-05 KR KR1020187019480A patent/KR20180085801A/en active Search and Examination
- 2016-12-05 MX MX2018006875A patent/MX2018006875A/en unknown
- 2016-12-05 RS RS20201201A patent/RS61029B1/en unknown
- 2016-12-05 PL PL16818985T patent/PL3386541T3/en unknown
- 2016-12-05 CN CN201680071740.1A patent/CN108367072B/en active Active
- 2016-12-05 EA EA201891339A patent/EA201891339A1/en unknown
- 2016-12-06 TW TW105140288A patent/TWI630917B/en active
- 2016-12-07 AR ARP160103760A patent/AR107014A1/en unknown
-
2018
- 2018-04-26 PH PH12018500894A patent/PH12018500894A1/en unknown
- 2018-05-23 IL IL259563A patent/IL259563B/en active IP Right Grant
- 2018-05-25 CO CONC2018/0005525A patent/CO2018005525A2/en unknown
- 2018-06-04 CL CL2018001488A patent/CL2018001488A1/en unknown
- 2018-06-06 SA SA518391743A patent/SA518391743B1/en unknown
- 2018-07-06 ZA ZA201804534A patent/ZA201804534B/en unknown
-
2019
- 2019-01-04 HK HK19100169.4A patent/HK1257781A1/en unknown
-
2020
- 2020-09-24 CY CY20201100904T patent/CY1123358T1/en unknown
- 2020-10-05 HR HRP20201573TT patent/HRP20201573T1/en unknown
- 2020-12-09 US US17/116,587 patent/US20210100903A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201804534B (en) | AQUEOUS PHARMACEUTICAL FORMULATION COMPRISING ANTI-PD-l-L1 ANTIBODY AVELUMAB | |
IL271226A (en) | Pharmaceutical formulation | |
PT3426294T (en) | Pharmaceutical formulation | |
IL253177B (en) | Pharmaceutical formulation | |
HK1245653A1 (en) | Pharmaceutical formulation | |
IL266537A (en) | Pharmaceutical formulation | |
ZA201807851B (en) | Pharmaceutical formulation | |
FI3601277T3 (en) | Pharmaceutical formulation | |
HUE054716T2 (en) | Pharmaceutical formulation comprising anti-egfr antibody | |
GB201506755D0 (en) | Novel pharmaceutical formulation | |
GB201511246D0 (en) | Pharmaceutical formulation | |
IL275144A (en) | Pharmaceutical formulation | |
GB201719873D0 (en) | Pharmaceutical formulation | |
GB201604545D0 (en) | Novel pharmaceutical formulation |